ICI conference 2017: new preclinical data further strengthen the rationale of IPH5401 and monalizumab for cancer treatments and in combination with anti-PD-1/PD-L1
Number of shares and voting rights of Innate Pharma as at August 4, 2017
Issuance by Innate Pharma of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for rights in anti-C5aR
Results of Annual General Meeting and changes to Innate Pharma’s governance and management team
Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
Innate Pharma strengthens its proprietary pipeline with the acquisition of anti-C5aR, a first-in-class clinical-stage antibody,from Novo Nordisk A/S
Innate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017
IPH4102: Completion of the dose escalation part of the Phase I trial - Data to be presented at International Conference on Malignant Lymphoma in June 2017 in Lugano
First quarter 2017 report
Number of shares and voting rights of Innate Pharma as at May 5, 2017
